1-Aryl-3,4-Dihydroisoquinoline Inhibitors of Jnk3.
Christopher, J.A., Atkinson, F.L., Bax, B.D., Brown, M.J., Champigny, A.C., Chuang, T.T., Jones, E.J., Mosley, J.E., Musgrave, J.R.(2009) Bioorg Med Chem Lett 19: 2230
- PubMed: 19303774 
- DOI: https://doi.org/10.1016/j.bmcl.2009.02.098
- Primary Citation of Related Structures:  
2WAJ - PubMed Abstract: 
A series of 1-aryl-3,4-dihydroisoquinoline inhibitors of JNK3 are described. Compounds 20 and 24 are the most potent inhibitors (pIC50 7.3 and 6.9, respectively in a radiometric filter binding assay), with 10- and 1000-fold selectivity over JNK2 and JNK1, respectively, and selectivity within the wider mitogen-activated protein kinase (MAPK) family against p38alpha and ERK2. X-ray crystallography of 16 reveals a highly unusual binding mode where an H-bond acceptor interaction with the hinge region is made by a chloro substituent.
Organizational Affiliation: 
GlaxoSmithKline R&D, Medicines Research Centre, Stevenage, Hertfordshire, UK. john@christopher257.fsnet.co.uk